Talquetamab Combinations for Multiple Myeloma
(MonumenTAL-6 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing two new drug combinations to treat multiple myeloma. The combinations include talquetamab with either pomalidomide or teclistamab. These drugs help the immune system better identify and destroy cancer cells. The goal is to see if these new combinations work better than existing treatments.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is Talquetamab safe for humans?
Talquetamab has been shown to be generally well-tolerated in clinical trials for multiple myeloma, with fewer infections compared to similar treatments, but it can cause side effects like skin, mouth, and nail issues. Teclistamab, a similar drug, has side effects such as cytokine release syndrome (a severe immune reaction), infections, and nerve problems, but is considered more tolerable for older patients.12345
What makes the drug Talquetamab combined with Teclistamab unique for treating multiple myeloma?
Talquetamab and Teclistamab are unique because they are bispecific antibodies that engage T-cells to target specific proteins on multiple myeloma cells, with Talquetamab targeting GPRC5D and Teclistamab targeting BCMA. This dual targeting approach is novel and offers a new option for patients who have relapsed or are resistant to other treatments.12356
What data supports the effectiveness of the drug Talquetamab for treating multiple myeloma?
Who Is on the Research Team?
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Are You a Good Fit for This Trial?
This trial is for people with multiple myeloma that has come back or hasn't responded to treatment, including an anti-CD38 antibody and lenalidomide. Participants should be fairly active (ECOG score of 0-2), not pregnant or planning pregnancy soon, and have measurable disease levels according to specific medical criteria.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Talquetamab plus Pomalidomide (Tal-P), Talquetamab plus Teclistamab (Tal-Tec), or Investigator's choice of Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd)
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Talquetamab
- Teclistamab
Talquetamab is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Joaquin Duato
Janssen Research & Development, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Research & Development, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University